Thirty-four of the 85 residues of the histidinecontaining protein HPr of the Escherichia coli phosphoenolpyruvate:sugar phosphotransferase system have been changed by site-directed mutagenesis. Many of the mutations have wild-type activity suggesting an unaltered tertiary struc-
, and its complex with HPr has recently been investigated (16) . The crystals of the complex were obtained using less severe conditions, pH 6.0 and 25% saturated ammonium sulfate, and thus offer another opportunity to determine the structure of HPr. However, to properly investigate either the structure of HPr or the potential effects of antibody binding on the antigen, HPr, it is important to determine which of the two HPr structures is the physiologically correct structure.
To aid in the assessment of the interactions between HPr and the antibodies, site-directed mutagenesis of putative surface residues has been carried out. It was realized that the mapping of the epitopes by studying the effects of residue changes on antibodies had the potential to discriminate between the two structures ofHPr. Sufficient information has now been accumulated to propose that the 2D-NMR is the structure most compatible with our present knowledge of epitopes in proteins (17, 18) and thus is probably the physiologically correct structure. Histidine-containing protein HPr from Escherichia coli is a small (85 amino acids) phosphocarrier protein of the phosphoenolpyruvate:sugar phosphotransferase system (PTS). HPr is phosphorylated by enzyme I, then transfers the phosphate group to sugar-specific components, either factor III or enzyme II, and ultimately leads to the phosphorylation and translocation of a number of sugars (1) (2) (3) (4) . The PTS has a number of regulatory interactions that result in major controls being imposed upon carbon-source utilization in E. coli and other bacteria (3) (4) (5) (6) (7) .
The three-dimensional structure of HPr has been determined by two independent methods: two-dimensional nuclear magnetic resonance (2D-NMR) studies of HPr in solution (8-10) and x-ray diffraction investigation of HPr crystals (11) . The structures determined by these methods are shown in Fig. 1 . They share the same secondary structure elements, three small a-helices, four strands of antiparallel (8-sheet, which in the 2D-NMR structure form a four-stranded sheet, but exist as two pairs in the x-ray diffraction structure. The active site components, His-15, Arg-17, and the C-terminal, Glu-85, are maintained in both structures. Clearly the tertiary structure folding is different, and as such these two structures represent one of the few major disagreements between structures determined by the two methods (12) . The only conditions under which HPr crystallized, pH 3.7 and 68% saturated lithium sulfate (11, 13) , could be considered harsh, and it has been proposed that the x-ray diffraction structure may be a partially unfolded HPr (11) .
There are three monoclonal antibodies that are specific for HPr: Jel42, Jel44, and Jel323 (14) . The three-dimensional structure of the Fab fragment of Jel42 has been described
MATERIALS AND METHODS
The monoclonal antibodies were prepared as described (14) . The gene for HPr (within a Cla I-Sma I DNA fragment) was obtained from H. Kornberg (19) in pAB65 and was transferred into the Acc I and Sma I restriction endonuclease cloning sites in pUC19 for protein overproduction and in M13mpll for oligonucleotide-dependent site-directed mutagenesis (20) .
HPr wild-type and mutant proteins were prepared from E. coli strain ES7 (14) , which was ptsH and was made recA. Some preparations were made from E. coli strain TP2811, which contained a deletion of the pts operon and was obtained from A. Danchin (21) . Four liters of LB broth with 100 gg of ampicillin per ml (20) yielded 20-30 g of wet weight cells from which 20-400 mg of HPr or mutant HPr was obtained. Purification of HPr involved the following: the removal of membranes by centrifugation; chromatography on Ultrogel AcA 54 (10 x 100 cm column) equilibrated with 10 mM Tris-HCl buffer (pH 7.5); chromatography on DEAEcellulose or Q Sepharose using the same buffer and eluting with gradients up to 0.3 M NaCl; lyophilization and then dialysis against 5 mM sodium acetate buffer (pH 5.5); chromatography on S Sepharose with the same buffer and gradients up to 0.5 M NaCl. This purification method is a rearrangement of the previous methods (22) . Mutated genes or pure proteins of some of the mutant HPrs were obtained from others ( Table 1 ). All preparation of these HPrs contained <1% of the deaminated product, HPr-1 (23) .
Site-directed mutagenesis was carried out using the general methods of Zoller and Smith (24) as modified by Kunkel (25 give adequate results, whereas double and triple base changes require primers up to 22 bases. Primers rich in adenosine and thymine residues needed to be longer. All mutations were confirmed by the complete sequencing of the open reading frame of the HPr gene.
The ability of the antibodies to bind to HPr and mutant HPrs was assessed using a competition solid-phase radioimmune assay as has been described (14) . Mutant HPr protein concentration was determined by the methods of Lowry et al. (26) and ofWaddell (27) using wild-type HPr as a control. The PTS activity of the HPr mutants was determined using an enzyme Ilma"nose assay as described (28) . The HPrs were assayed as substrates of enzyme 11mannose using concentrations of about 1, 2, and 4 /LM. These concentrations represent the part of the Michaelis-Menten function that approximates a first-order relationship, and the activity ofmutant HPrs was expressed as a percentage of the response given by wild-type HPr. Higher concentrations of mutant HPrs were used when activities were low.
The space-filling models of HPr were generated using the RASTER3D program written by D. Bacon (University of Alberta) and modified by A. Beghuis and M. E. Murphy (University of British Columbia). The structures used are the published structures (10, 11).
RESULTS
The experimental approach and conclusions are based upon the following rationale. The three-dimensional structures of several protein antigens with monoclonal Fab fragments have been described (17, 18, (29) (30) (31) . These reports indicate that the surface area comprising epitopes on proteins can vary between 680 and 880 A2 and involve about 14-21 surfaceexposed residues, essentially all of which are in a continguous area. The best-described system involves lysozyme as the protein antigen. Lysozyme (Mr 14,388) is larger than HPr (Mr 9017), but both are small proteins, and thus lysozyme is a reasonable molecule for comparison. If, as is the situation for HPr, there were two proposed tertiary structures for a protein, then a discontinuous epitope on the correct structure should form a contiguous area, whereas in the other structure, the residues identified as being part of this epitope could be dispersed throughout the structure. If surface-exposed residues were changed by mutagenesis such that they did not cause general structural changes, then the epitopes could be mapped by measuring the effect or lack of effect of the changes on antibody binding. A discrimination between the two structures could then be made by examining the location of residues on the two structures.
A large number of residues in HPr have been changed by mutagenesis (Table 1) , and their effects on antibody binding have been assessed using a sensitive competition assay (14) .
It would appear that radical changes can often be made to surface residues, without causing general structural rearrangements. The lack of structural rearrangement was assessed in the following ways: changes to HPr activity; the detection of a significant change in binding with one antibody but little or no changes for the other antibodies. This latter assessment was compromised because the results suggest that Jel42 and Jel44 have overlapping epitopes.
Many of the mutant HPrs had small (±20%o) or no changes in activity. The activity assays have a reliability of about ±10%1 of the values given. However, some mutant HPrs had significant changes. Mutants V6F, E68A, and D69E have significant activity changes, but they cause only minor changes to the ability ofthe antibodies to bind to the epitopes. Mutations of residues at or near the active site, residues 17 and 83-85, all gave expected losses in activity, but apart from termination at residue 83 none of them is involved in the epitopes. Residue 83 was changed to alanine and gave a change in antibody binding without the concomitant loss in activity. Some mutants with low activity, K24E and the double mutant, F48M, M49G, appear to be involved with only the epitope of Jel323, suggesting that the structural changes are limited. Similarly, S41K and E66K are very specific for Jel42. One mutant, T34N, resulted in a change in antibody binding for all three monoclonal antibodies. T34N had no detectable PTS activity; thus it may have been a disrupted structure. The T34Q mutation suggests that Thr-34 is not a residue involved with the epitopes. Phe-2 when changed to Tyr-2 did not alter Jel42 binding or PTS activity, yet the subsequent examination of both of the structures of HPr (see below) indicated that this residue was in the middle of the Jel42 epitope. The subsequent mutation to Trp-2 yielded the result expected from examination of the structures but resulted in a loss in activity. Residues 2 and 66-72 are located close to each other in the 2D-NMR structure (Fig.  1) , and residues 66-72 form a loop between the last strand of /-sheet structure and the C-terminal a-helix. In both structures these residues are not in the vicinity of the active site, yet the integrity of residues in this region appears to be required for activity.
Most mutations gave no change in the binding of at least one antibody. Between the three antibodies, about 50%o ofthe surface of HPr is being monitored. Given that a 10-fold change in binding can be equated to one hydrogen bond formed or disrupted, these antibodies provide a sensitive surface-monitoring system. Collectively, the results in Table  1 suggest that the Jel323 epitope determinants are largely independent of those for Jel42 or Jel44, whereas Jel42 and Jel44 epitopes are different but overlapping. Some mutants gave small changes to antibody binding (2- fold or 3-fold) . For Jel42 and Jel44, the 2-fold changes have been grouped with those giving no change in binding for the purpose of description of the epitopes. This is because they represent measurements at the limit of our confidence in the competition assay. The competition assay with Jel323 showed more variation, and values up to 3-fold changes in binding were not considered definitive.
In the space-filling models of HPr that follow (Figs. 2 and  3) , residues whose mutation changes antibody binding are colored deep and pale blue for significant and weak changes, respectively. The division between these is arbitrary but reflects our assessment of the alteration: "significant" is any change giving at least a 10-fold change in binding, whereas a "weak" change is between 3-and 10-fold.
The residues that have been identified as part of the Jel44 epitope are shown in Fig. 2 . "Back and front" views (resulting from a 1800 rotation about the horizontal axis) of the 2D-NMR ( Fig. 2A) and the x-ray diffraction (Fig. 2B ) structures revealed a contiguous area of the epitope (blue colors) in the 2D-NMR structure, which is uninterrupted by those residues (brown) that apparently have no involvement. In the center of the epitope, three residues whose side chains have limited surface exposure in the 2D-NMR structure have not been mutated. These are Ala-73, Val-74, and Leu-77, which make up part of the hydrophobic core of HPr in the 2D-NMR structure. Mutation of such residues could cause packing and folding distortions. In general, the residues are located in the 2D-NMR structure in a pattern that is consistent with our present understanding of a protein epitope. In contrast, the same residues when located in the x-ray diffraction structure (Fig. 2B) are found scattered throughout the molecule, some buried, and generally mixed among noninvolved residues. Residues Glu-75 and Glu-83 would appear to be major determinants in the epitope, yet they are essentially buried within the HPr structure that was determined by x-ray diffraction. In addition, Ser-64, His-76, and Lys-79 with apparent weaker contributions are essentially buried, and in fact Lys-79 is primarily exposed on the back of the molecule. In contrast, all of these residues have good surface exposure in the 2D-NMR structure.
The residues (blue colors) identified in the Jel42 epitope are shown in Fig. 3 A and B . Clearly, the residues form a contiguous area on both structures. The epitope has components that are discontinuous but that are close to each other in both structures. The N-terminal methionine residue is the prominent nonmutated residue in the center of the epitope and would appear to be part of the epitope. It may be part of the Jel44 epitope ( Fig. 2A) . This cannot easily be changed as it is the translational initiation site. There are two residues, Glu-75 and His-76, that cause changes to Jel42 binding that are buried in the x-ray structure, whereas they are surface exposed on the 2D-NMR structure.
The results in Table 1 clearly indicate that Jel323 epitope is distinct from the other epitopes. There are only a few antigenic determinants yet identified for Jel323 (Fig. 2C) , most of which also inhibit PTS activity. In the 2D-NMR structure, the Jel323 epitope residues are located primarily on the "side" opposite to the Jel44 epitope and are not interspersed with residues that were identified as not being part of the epitope. In contrast, the same Jel323 epitope residues located on the x-ray diffraction structure are dispersed among residues that have no effect on antibody binding. Fig. 3B.   FIG. 3 . Jel42 epitope. The residues in HPr for which mutation causes an alteration in Jel42 binding are colored blue, and other residues are colored as described in the legend to Fig. 2. (A) 2D-NMR structure. (B) X-ray diffraction structure.
DISCUSSION
Application of x-ray diffraction and 2D-NMR techniques to the determination of protein structures has for the most part resulted in considerable agreement. The two threedimensional structures determined for HPr have presented one of the major deviations (12) . The results of epitope mapping presented here indicate that the structure being recognized by the antibodies, in particular for Jel44, is consistent with that determined by 2D-NMR. Jel42 binds to a surface that is contiguous in both structures, which is consistent with the fact that the two structures, although different, share common features. It would therefore appear that the 2D-NMR structure is the one present under physiological conditions.
Neither of the structures for HPr is a high-resolution structure. The x-ray structure was determined to 2.8 A and had an R value of 23% (11) . The 2D-NMR structure is also an initial structure (10) . It has been proposed that the structure determined by x-ray diffraction may be a partially unfolded protein, and this view would appear to be the most likely explanation for the differences (11 
